State
of New York
|
1-10113
|
11-0853640
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
of
Incorporation)
|
Identification
Number)
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17CFR240.14d 2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e 4(c))
|
Exhibit
Number
|
Description
|
99.1
|
Press
Release dated May 4, 2007 Announcing Financial Results for the First
Quarter of 2007
|
ACURA
PHARMACEUTICALS, INC.
|
||
By:
|
/s/
Peter A. Clemens
|
|
Peter
A. Clemens
|
||
Senior
Vice President & Chief Financial
Officer
|
Exhibit
Number
|
Description
|
99.1
|
Press
Release dated May 4, 2007 Announcing Financial Results for the First
Quarter of 2007
|
ACURA
PHARMACEUTICALS, INC.
|
|||||||
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
|||||||
(in
thousands)
|
|||||||
(Unaudited)
|
(Audited)
|
||||||
March
31,
|
December
31,
|
||||||
2007
|
2006
|
||||||
Current
Assets
|
$ |
680
|
$ |
467
|
|||
Property,
Plant and Equipment, net
|
1,143
|
1,145
|
|||||
Other
Assets
|
7
|
7
|
|||||
Total
Assets
|
$ |
1,830
|
$ |
1,619
|
|||
Accrued
Expenses
|
757
|
328
|
|||||
Stock
Warrants
|
-
|
10,784
|
|||||
Debt,
net
|
13,831
|
28,787
|
|||||
Stockholders'
Deficit
|
(12,758
|
)
|
(38,280
|
)
|
|||
Total
Liabilities and Stockholders' Deficit
|
$ |
1,830
|
$ |
1,619
|
ACURA
PHARMACEUTICALS, INC.
|
|||||||
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|||||||
(in
thousands, except per share data)
|
|||||||
(Unaudited)
Three
Months Ended Mar 31,
|
|||||||
Operating
Costs
|
2007
|
2006
|
|||||
Research
and Development
|
$ |
1,196
|
$ |
1,506
|
|||
Marketing,
General and Administrative
|
778
|
2,421
|
|||||
Loss
from Operations
|
(1,974
|
)
|
(3,927
|
)
|
|||
Other
(Expense) Income
|
|||||||
Interest
Expense
|
(367
|
)
|
(225
|
)
|
|||
Interest
Income
|
5
|
4
|
|||||
Amortization
of Debt Discount
|
(1,692
|
)
|
-
|
||||
Loss
on Fair Value Change of
Conversion
Features
|
(3,483
|
)
|
-
|
||||
Loss
on Fair Value Change of
Common
Stock Warrants
|
(1,668
|
)
|
-
|
||||
Gain
(Loss) on Asset Disposals
|
20
|
(7
|
)
|
||||
Total
Other (Expense) Income
|
(7,185
|
)
|
(228
|
)
|
|||
Net
Loss
|
$ |
(9,159
|
)
|
$ |
(4,155
|
)
|
|
Basic
and Diluted Loss Per Common Share
Allocable
to Common Stockholders
|
$ |
(0.03
|
)
|
$ |
(0.01
|
)
|
|
Weighted
Average Shares Used in Computing
Basic
and Diluted Loss Per Share
Allocable
to Common Stockholders
|
352,293
|
340,314
|